Abdou E, Pedapenki RM, Abouagour M, Zar AR, et al. Patient selection and risk factors in the changing treatment landscape of metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2020;20(10):831–40.

Article  CAS  PubMed  Google Scholar 

Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, et al. European Association of Urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol. 2022;82(4):399–410.

Article  PubMed  Google Scholar 

Powles T, Albiges L, Bex A, Comperat E et al. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;S0923-7534(24)00676-8.

Motzer RJ, Jonasch E, Agarwal N, Alva A, et al. NCCN Guidelines® insights: kidney cancer, version 2.2024. J Natl Compr Canc Netw. 2024;22(1):4–16.

Article  CAS  PubMed  Google Scholar 

Leitlinienprogramm_Onkologie. Konsultationsfassung S. 3-Leitlinie Diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms 2024 [Version 5.01 – Juli 2024: https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/LL_Nierenzellkarzinom_Langversion_5.01.pdf. Accessed August 2024.

Grimm MO, Leucht K, Foller S. Risk stratification and treatment algorithm of metastatic renal cell carcinoma. J Clin Med. 2021;10(22):5339.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heseltine J, Allison J, Wong S, Prasad K, et al. Clinical outcomes of Tivozanib Monotherapy as First-Line treatment for metastatic renal cell carcinoma: a Multicentric UK Real-World Analysis. Target Oncol. 2023;18(4):593–9.

Article  PubMed  Google Scholar 

Salgia NJ, Philip EJ, Ziari M, Yap K, et al. Advancing the Science and Management of Renal Cell Carcinoma: bridging the divide between Academic and Community practices. J Clin Med. 2020;9(5):1508.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gill DM, Agarwal N, Vaishampayan U. Evolving treatment paradigm in metastatic renal cell carcinoma. Am Soc Clin Oncol Educ Book. 2017;37:319–29.

Article  PubMed  PubMed Central  Google Scholar 

Qin S, Li A, Yi M, Yu S et al. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hem Oncol. 2019;12.

Parikh M, Bajwa P. Immune checkpoint inhibitors in the treatment of renal cell carcinoma. Semin Nephrol. 2020;40(1):76–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee D, Gittleman H, Weinstock C, Suzman D, et al. A U.S. Food and Drug Administration-pooled analysis of Frontline Combination Treatment Survival benefits by risk groups in metastatic renal cell carcinoma. Eur Urol. 2023;84(4):373–8.

Article  CAS  PubMed  Google Scholar 

National Cancer Institute. Drugs Approved for Kidney Cancer 2023 https://www.cancer.gov/about-cancer/treatment/drugs/kidney. Accessed December 2023.

van Laar SA, Gombert-Handoko KB, Groenwold RHH, van der Hulle T et al. Real-world metastatic renal cell carcinoma treatment patterns and clinical outcomes in the Netherlands. Front Pharmacol. 2022;13.

Food and Drug Administration. FDA Approves Belzutifan for Advanced Renal Cell Carcinoma. https://wwwfdagov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-advanced-renal-cell-carcinoma. Accessed Feb 2024.

European Medicines Agency. Medicines for Human Use Under Evaluation. https://www.emaeuropaeu/en/medicines/medicines-human-use-under-evaluation. Accessed July 2024.

Quivy A, Daste A, Harbaoui A, Duc S, et al. Optimal management of renal cell carcinoma in the elderly: a review. Clin Interv Aging. 2013;8:433–42.

PubMed  PubMed Central  Google Scholar 

Costello BA, Bhavsar NA, Zakharia Y, Pal SK, et al. A prospective multicenter evaluation of initial treatment choice in metastatic renal cell carcinoma prior to the immunotherapy era: the MaRCC registry experience. Clin Genitourin Cancer. 2022;20(1):1–10.

Article  PubMed  Google Scholar 

Yanagisawa T, Quhal F, Kawada T, Bekku K, et al. Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: a meta-analysis. Immunotherapy. 2023;15(15):1309–22.

Article  CAS  PubMed  Google Scholar 

Aldin A, Besiroglu B, Adams A, Monsef I, et al. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023;5(5):Cd013798.

PubMed  Google Scholar 

Heng DY, Xie W, Regan MM, Warren MA, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–9.

Article  CAS  PubMed  Google Scholar 

Heng DY, Xie W, Regan MM, Harshman LC, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141–8.

Article  PubMed  PubMed Central  Google Scholar 

Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, et al. Patterns of gene expression and copy-number alterations in Von-Hippel Lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 2009;69(11):4674–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scelo G, Riazalhosseini Y, Greger L, Letourneau L, et al. Variation in genomic landscape of clear cell renal cell carcinoma across Europe. Nat Commun. 2014;5:5135.

Article  CAS  PubMed  Google Scholar 

Kaelin WG Jr., Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008;30(4):393–402.

Article  CAS  PubMed  Google Scholar 

Krieg M, Haas R, Brauch H, Acker T, et al. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by Von Hippel-Lindau tumor suppressor gene loss of function. Oncogene. 2000;19(48):5435–43.

Article  CAS  PubMed  Google Scholar 

Li L, Kaelin WG. Jr. New insights into the biology of renal cell carcinoma. Hematol Oncol Clin North Am. 2011;25(4):667–86.

Article  PubMed  PubMed Central  Google Scholar 

Thompson RH, Dong H, Lohse CM, Leibovich BC, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007;13(6):1757–61.

Article  CAS  PubMed  Google Scholar 

Motzer RJ, Powles T, Atkins MB, Escudier B, et al. Final Overall Survival and Molecular Analysis in IMmotion151, a phase 3 trial comparing Atezolizumab Plus Bevacizumab vs Sunitinib in patients with previously untreated metastatic renal cell carcinoma. JAMA Oncol. 2022;8(2):275–80.

Article  PubMed  Google Scholar 

D’Costa NM, Cina D, Shrestha R, Bell RH, et al. Identification of gene signature for treatment response to guide precision oncology in clear-cell renal cell carcinoma. Sci Rep. 2020;10(1):2026.

Article  PubMed  PubMed Central  Google Scholar 

Santos M, Lanillos J, Caleiras E, Valdivia C, et al. PBRM1 and KDM5C cooperate to define high-angiogenesis tumors and increased antiangiogenic response in renal cancer. Am J Cancer Res. 2023;13(5):2116–25.

CAS  PubMed  PubMed Central  Google Scholar 

Beuselinck B, Verbiest A, Couchy G, Job S, et al. Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma. Acta Oncol. 2018;57(4):498–508.

Article  CAS  PubMed  Google Scholar 

Motzer RJ, Banchereau R, Hamidi H, Powles T, et al. Molecular subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. Cancer Cell. 2020;38(6):803–e174.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saliby RM, Labaki C, Jammihal TR, Xie W, et al. Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes. Cancer Cell. 2024;42(5):732–5.

Article  CAS  PubMed  Google Scholar 

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378(14):1277–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Epaillard N, Simonaggio A, Elaidi R, Azzouz F, et al. BIONIKK: a phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer. Bull Cancer. 2020;107(5s):eS22–7.

Article